Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Lymphoma

Lymphoma

1.4K

Pipeline Programs↗

534

Active Trials↗

323

Companies Involved↗

Lymphoma is a highly competitive landscape with 1438 programs across 323 companies. The most active players are AstraZeneca, Bristol-Myers Squibb, Roche. 69 therapies are approved with 147 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

81/100

Mech. Concentration

4/100

Completion Rate

74/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

AstraZeneca

9 programs

Bristol-Myers Squibb

7 programs

Phase 1/Phase 2

Roche

6 programs

Phase 1/Phase 2

Novartis

5 programs

Johnson & Johnson

5 programs

Phase 1/Phase 2

Amgen

3 programs

Pipeline

Programs by Phase

Preclinical79

Bleomycin Sulfate

Sequus Pharmaceuticals

Vinblastine Sulfate

Eastern Cooperative Oncology Group

Tafasitamab

Incyte

Rasburicase

Azienda U.S.L. 1 di Massa e Carrara

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Phase 1504

Veliparib

AbbVie

Vemurafenib

Conrado Roberto Hoffmann Filho

Trastuzumab

Roche

Tanespimycin

Bristol-Myers Squibb

Alefacept

Astellas

Phase 2639

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Isatuximab

Azienda U.S.L. 1 di Massa e Carrara

Cemiplimab

Regeneron

TAZEMETOSTAT

Epizyme, Inc.

Antineoplaston A10

Burzynski Research Institute

Phase 3147

Asparaginase

Dutch Childhood Oncology Group

Brentuximab Vedotin

Pfizer

Tocilizumab

Roche

Idelalisib

Gilead

Glofitamab

Roche

Approved69

Vinblastine

Eli Lilly

Exemestane

Pfizer

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Dacarbazine

Bayer

Abemaciclib

Eli Lilly

Analysis

Modality Breakdown

78%

Small molecule

1,219 of 1,571 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 1,571 classified programs, each share of the total. Modality classified for 100% of 1,784 pipeline programs.

Analysis

Trial Status

2,581

clinical trials

Completed1,189 · 46%

Unknown status427 · 17%

Terminated326 · 13%

Recruiting310 · 12%

Active, not recruiting136 · 5%

Withdrawn93 · 4%

Other100 · 4%

Clinical Trials

Trial Activity

2581 trials

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Recruiting·—·Phase 2·NCT05833893·10 enrolled

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting·SSIRPant Immunotherapeutics, Inc.·Phase 1·NCT05967416·24 enrolled

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Recruiting·GGALIA AVRAHAMI·N/A·NCT02797717·2,200 enrolled

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting·SSun Yat-sen University·Phase 1/2·NCT07093710·101 enrolled

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Recruiting·—·Phase 1/2·NCT07009002·30 enrolled

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting·FFondazione Italiana Linfomi - ETS·Phase 1/2·NCT05300282·122 enrolled

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

Recruiting·TThe First Hospital of Jilin University·Phase 1/2·NCT06592170·35 enrolled

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 1/2·NCT05934513·95 enrolled

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

Recruiting·HHaihe Biopharma Co., Ltd.·Phase 1/2·NCT06909877·100 enrolled

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Recruiting·SSuzhou Immunofoco Biotechnology Co., Ltd·Phase 1/2·NCT07376642·30 enrolled

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Recruiting·SSecuraBio·Phase 3·NCT06522737·124 enrolled

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05355051·24 enrolled

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Recruiting·OOncoNano Medicine, Inc.·Phase 1·NCT06022029·168 enrolled

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Recruiting·IImmune Oncology Research Institute·Phase 2·NCT05891821·20 enrolled

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting·FFondazione Italiana Linfomi - ETS·N/A·NCT06008691·1,500 enrolled

Page 1 of 173

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)